Mode
Text Size
Log in / Sign up
N/A Completed N=1,264

Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example

Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT01036763 ↗
Enrolled (actual)
1,264
Serious AEs
0.4%
Results posted
Mar 2012
Primary outcomePrimary: Success of Treatment With Tiotropium According to Physician's Assessment — 620; 618; 452; 412 Participants

Summary

Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according to the physicians assessment to determine the success of therapy. Such data are not yet available. Also collection of physicians assessments and patients assessments of efficacy and tolerability of Spiriva Respimat, Spiriva (tiotropium 18 mcg capsules).

Outcome Measures

OutcomeResultp-value
PRIMARY
Success of Treatment With Tiotropium According to Physician's Assessment
620; 618; 452; 412; 235; 106 —
PRIMARY
Assessment of Efficacy According to Physician
342; 645; 172; 44; 27; 34 —
PRIMARY
Assessment of Tolerability According to Physician
601; 572; 35; 9; 13; 34 —
PRIMARY
Assessment of Efficacy According to Patient
339; 620; 169; 55; 35; 46 —
PRIMARY
Assessment of Tolerability According to Patient
564; 567; 54; 14; 17; 48 —
SECONDARY
Physician's Global Evaluation at Visit 1
8; 294; 755; 206; 1 —
SECONDARY
Physician's Global Evaluation at Visit 2
61; 737; 407; 31; 28 —

Eligibility Criteria

Inclusion criteria COPD patients requiring long-acting bronchodilators according to approved Summary of Product Characteristics (SPC) and guidelines Exclusion criteria Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01036763). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search